|
Steven Oh
Acting Director, Division of Cell Therapy 1 & 2
FDA
Silver Spring, MD
USA
|
Dr. Steven Oh is Acting Director of Division of Cell Therapy 1 and Division of Cell Therapy 2 within Office of Cellular Therapy and Human Tissue (OCTHT) in CBER, FDA. In this role, he oversees the product quality review program and regulatory activities focused on cell therapy products, tissue-engineered products, and related medical devices used at the point-of-care. He is also the head of the bioinformatics regulatory group in OCTHT. In addition, Dr. Oh is involved in developing policies related to emerging technologies in regenerative therapies and individualized medicine, standards development and use, and global regulatory convergence in cell therapies, tissue-engineered products, and other advanced therapy products. Before joining FDA in 2007, Dr. Oh served on the faculty of Tufts University School of Medicine. He was trained as a cell biologist and biochemist at the University of Michigan, Johns Hopkins University School of Medicine, and Massachusetts Institute of Technology.